Why Ligand Pharmaceuticals (LGND) Could Be an Impressive Growth Stock - Tale of the Tape

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is Ligand Pharmaceuticals Incorporated (LGND). This firm, which is in the biotechnology space, saw EPS growth of 57.1% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for earnings-per-share growth of over 100%. Furthermore, the long-term growth rate is currently an impressive 30%, suggesting pretty good prospects for the long haul.

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 18%. Thanks to this rise in earnings estimates, LGND has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company.

So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider LGND. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for LGND as well.

Want the latest recommendations from Zacks Investment Research? Today, you can download7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
LIGAND PHARMA-B (LGND): Free Stock Analysis Report
 
To read this article on Zacks.com click here.